CA2480783C — An improved modified release preparation
Assigned to Mayne Pharma International Pty Ltd · Expires 2010-01-19 · 16y expired
What this patent protects
A modified release preparation having one or more coated core elements. Each core element includes an active ingredient and has a modified release coating. A stablising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution…
USPTO Abstract
A modified release preparation having one or more coated core elements. Each core element includes an active ingredient and has a modified release coating. A stablising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile. The invention also provides a method of administering an active ingredient that, upon administration in an immediate release form, normally causes nausea and gastric irritation, the method including administering a modified release preparation of the invention.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.